Syneos Health announced on 14th May 2026 a series of new and expanded AI partnerships aimed at advancing its AI ecosystem and strengthening commercial precision capabilities for biopharma companies. The company said the latest collaborations bring together best-in-breed technologies designed to improve healthcare provider (HCP) engagement while helping organizations accelerate decision-making and execution across commercial operations. The move further reinforces the company’s strategy of embedding artificial intelligence directly into operational workflows to support faster and more targeted actions. According to Syneos Health, these AI partnerships are already contributing measurable value through customer co-creation initiatives intended to shape the future of healthcare.
“We’re deploying AI where it drives measurable outcomes – helping clients optimize what works, predict what matters and automate execution to improve brand performance,” said Stephen Hoelper, Global Head, Commercial Product, Syneos Health.
“In the HCP space, that means faster decisions, more effective engagement and stronger launch and market results,” he added.
The company stated that the AI partnerships enhance Kinetic, its commercial intelligence engine launched in 2020 to connect proprietary and partner intelligence into a continuously learning system. Syneos Health noted that Kinetic converts domain expertise into actionable insights that help strengthen HCP relationships, streamline scientific discussions and accelerate complex commercial decisions.
Kinetic is Syneos Health’s AI-powered commercial intelligence engine that combines advanced AI, behavioral intelligence and Syneos Health expertise to help biopharma organizations optimize commercial performance at scale.
Among the expanded AI partnerships, Syneos Health highlighted its collaboration with KAI Conversations, whose AI-powered conversation intelligence platform is currently used by 10 of the top 20 global pharmaceutical companies. The technology transforms interactions between field teams and HCPs into structured intelligence while also supporting individualized coaching for sales representatives, and generates aggregated brand and customer insights for commercial and medical leaders to enhance messaging and bolster HCP relationships.
In addition, the company has deployed Sageforce’s AI-powered field teams, including AI MSLs, field reimbursement managers, nurse navigators and virtual sales representatives developed by AI and neuroscience experts specifically for healthcare and life sciences. Syneos Health said this hybrid engagement approach increases reach, frequency and overall engagement impact. The company added that AI MSLs can proactively engage HCPs using approved scientific content while triaging more complex discussions to human MSLs in real time.
Further expanding its AI partnerships, Syneos Health also announced the deployment of causal AI agents through causaLens to support commercial operations. The agents are designed to assist customers in moving beyond correlation-based analysis by delivering explainable and production-ready insights in highly regulated environments like pharmaceuticals and healthcare. According to the company, the technology supports HCP targeting and scoring, engagement optimization, territory planning and continuous optimization of channel mix, media and execution.
These capabilities complement Syneos Health’s proprietary intelligence offerings, including Mindset Engine, a behavioral intelligence system built to understand HCP decision-making patterns using evidence-based behavioral drivers from nearly 14,000 HCPs across more than 30 specialties and multiple countries.
Syneos Health said the continued integration of advanced AI capabilities across its commercial suite is intended to modernize how brands launch products, engage HCPs and improve in-market performance.
